GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

NCT01274182 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: GP2013
BIOLOGICAL: MabThera
BIOLOGICAL: Rituxan

Sponsor

Sandoz

Collaborators

[object Object]